Edgewise Therapeutics, INC

Edgewise Therapeutics files an 8-K/A to amend its previous report, providing pro forma financial information following the $1.55 billion sale of its sevasemten muscular dystrophy program to Servier Pharmaceuticals.

Edgewise Therapeutics has completed the sale of its sevasemten compound and related assets for its muscular dystrophy program to Servier Pharmaceuticals for up to $2.65 billion, allowing it to focus on its cardiovascular pipeline.

Edgewise Therapeutics stockholders re-elected three directors and ratified the appointment of KPMG LLP as the company's independent auditor.

Edgewise Therapeutics announces the sale of its sevasemten asset and muscular dystrophy business to Servier for up to $2.65 billion, shifting focus to its cardiovascular pipeline.

Edgewise Therapeutics reports Q1 2026 results, highlighting positive long-term data for sevasemten in Becker muscular dystrophy and advancing its HCM and heart failure programs.

Edgewise Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant progress in its muscular dystrophy and cardiovascular clinical programs with key data readouts expected in 2026.

Edgewise Therapeutics reported a wider net loss for Q1 2026 compared to the prior year, driven by increased research and development expenses.

Edgewise Therapeutics reported increased net losses in Q3 2025 and for the nine months ended September 30, 2025, driven by expanded research and development activities for its muscle disease pipeline, while maintaining a strong cash position.

Edgewise Therapeutics reported increased R&D expenses and net losses in Q2 2025, while maintaining a strong cash position of $594 million to fund operations for at least the next 12 months, driven by recent equity offerings and ongoing clinical trial advancements.

Edgewise Therapeutics reports a net loss of $40.8 million for Q1 2025, alongside updates on its clinical programs and financial position.

Edgewise Therapeutics reports a net loss of $34.1 million for Q3 2024, alongside updates on clinical trials and financial position.

Edgewise Therapeutics, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical trials and financial activities.

Edgewise Therapeutics, Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, detailing significant progress in its muscular dystrophy and cardiac disease clinical programs, alongside increased net losses and ongoing capital requirements.

Edgewise Therapeutics' 10-K filing summarizes the company's focus on developing treatments for severe muscle diseases, highlighting clinical progress with sevasemten and EDG-7500, and detailing financial performance and future strategies.

Edgewise Therapeutics continues to advance its clinical programs for muscle diseases, reporting progress in multiple Phase 2 trials and a Phase 1 trial, while also highlighting its proprietary drug discovery platform.

Jonathan D Root, a Director of Edgewise Therapeutics, Inc., received 16,377 shares of common stock on June 5, 2026.

Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, Inc., reported transactions involving the acquisition and disposition of common stock and stock options on July 1, 2026.

Jonathan C. Fox, a Director at Edgewise Therapeutics, Inc., received a restricted stock unit award on July 1, 2026, as part of his quarterly retainer.

Director Laura Brege was granted 16,377 stock options in Edgewise Therapeutics, Inc. as part of a standard equity compensation arrangement.

Peter A. Thompson, a Director and 10% Owner of Edgewise Therapeutics, Inc., acquired stock options on June 5, 2026, with a vesting schedule tied to future annual meetings.

Arlene Morris, a Director at Edgewise Therapeutics, Inc., reported the acquisition of stock options on June 5, 2026, with vesting conditions tied to future annual meetings.

Edgewise Therapeutics announces its 2026 Annual Meeting of Stockholders, detailing director elections, auditor ratification, and executive compensation.

Edgewise Therapeutics issues a supplement to its definitive proxy statement to correct the number of outstanding shares and the class of directors being elected at the annual meeting.

Edgewise Therapeutics announces its 2025 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and executive compensation votes.

Edgewise Therapeutics sets date for annual stockholder meeting, proposes director elections, and seeks ratification of accounting firm appointment.

Edgewise Therapeutics appoints Arlene Morris, a biotech industry veteran, to its Board of Directors, effective May 6, 2024.

Edgewise Therapeutics announces its 2024 Annual Meeting of Stockholders to be held on June 7, 2024, with key proposals including the election of directors, ratification of KPMG LLP as the independent accounting firm, and approval of an amendment to limit officer liability.

Novo Holdings A/S reports a decrease in beneficial ownership of Edgewise Therapeutics, Inc. common stock to below the 5% threshold due to dilution.

OrbiMed Advisors and its affiliated entities have filed an Amendment No. 4 to their Schedule 13D, reporting a decrease in their beneficial ownership percentage of Edgewise Therapeutics, Inc. common stock to 14.5% due to an increase in the total outstanding shares of the issuer.

Janus Henderson Group plc has reported beneficial ownership of 5.5% of Edgewise Therapeutics, Inc. common stock as of March 31, 2026.

RA Capital Management and its affiliates have disclosed a 9.9% beneficial ownership stake in Edgewise Therapeutics, Inc., totaling 10,428,437 shares of common stock.

Janus Henderson Group plc has disclosed a 4.7% beneficial ownership stake in Edgewise Therapeutics, Inc., holding 4,979,331 common shares.

Perceptive Advisors and related entities report a 4.4% beneficial ownership in Edgewise Therapeutics, holding 4,639,949 shares.

Baker Bros. Advisors and its affiliates have disclosed a 6.9% beneficial ownership stake in Edgewise Therapeutics, Inc., holding over 7.3 million shares.

Janus Henderson Group plc has reported an increased beneficial ownership of 5.2% in Edgewise Therapeutics, holding 5,503,349 common shares.